Abgenix Inc.'s belt-tightening move that consolidates its research and preclinical activities into its Canadian facility in Burnaby, British Columbia, and lays off about 15 percent of its work force will give the firm more resources to direct toward panitumumab, the fully human monoclonal antibody for colorectal cancer partnered with Amgen Inc. (BioWorld Today)
Cubist Pharmaceuticals Inc. said its Phase III trial with Cubicin (daptomycin) hit its primary endpoints against Staphylococcus aureus endocarditis and bacteremia, and the company has a supplementary new drug application in the works. (BioWorld Today)
Three months after Myogen Inc.'s lead drug candidate for heart failure, enoximone, missed statistical significance in the primary endpoint of a Phase III trial - an event the company blamed on unexpected improvements in patients given placebo - the compound has failed in top-line results from two more Phase III studies. (BioWorld Today)
Aiming to file a biologics license application in 2007, Dynavax Technologies Inc. began a pivotal Phase III trial to test its Toll-like receptor 9 hepatitis B vaccine against the efficacy of Engerix-B, GlaxoSmithKline plc's HBV vaccine, in older adults. (BioWorld Today)
In a bid to fuse diagnostics with pharmacogenomics, Clinical Data Inc. is taking over Genaissance Pharmaceuticals Inc. in an all-stock deal valued at about $56 million. (BioWorld Today)
